

PRIOR AUTHORIZATION POLICY

POLICY: Inflammatory Conditions – Velsipity Prior Authorization Policy

- Velsipity® (etrasimod tablets – Pfizer)

REVIEW DATE: 11/08/2023

OVERVIEW

Velsipity, a sphingosine 1-phosphate receptor modulator, is indicated for the treatment of **ulcerative colitis** (UC), in adults with moderately to severely active disease.¹

Guidelines/Clinical Efficacy

Velsipity is not currently addressed in UC guidelines. The American Gastroenterological Association (2020) and the American College of Gastroenterology (2019) have clinical practice guidelines on the management of moderate to severe UC and make recommendations for induction and maintenance of remission in adults.^{2,3} Both endorse the use of biologic agents and give specific patient circumstances in the selection for induction and maintenance therapies. Pivotal trials for Velsipity included adults with moderately to severely active UC who had an inadequate response or were intolerant to any of the following agents: oral aminosalicylates, corticosteroids, immunomodulators (e.g., 6-mercaptopurine and azathioprine), or a biologic (e.g., tumor necrosis factor inhibitor, Entyvio® [vedolizumab injection], or a Janus kinase inhibitor (e.g., Xeljanz® [tofacitinib tablets]).¹

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Velsipity. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Velsipity as well as the monitoring required for adverse events and long-term efficacy, approval requires Velsipity to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Velsipity is recommended in those who meet one of the following criteria:

FDA-Approved Indications

- 1. Ulcerative Colitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
 - A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):
 - i.** Patient is ≥ 18 years of age; AND
 - ii.** Patient has had a trial of ONE systemic agent for ulcerative colitis; AND
Note: Examples of systemic agents for ulcerative colitis include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone, methylprednisolone. A trial of one biologic also counts as a trial of one systemic agent for ulcerative colitis. Refer to the [Appendix](#) for examples of biologics used for ulcerative colitis.
 - iii.** The medication is prescribed by or in consultation with a gastroenterologist.

11/08/2023

© 2023. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

- B) Patient is Currently Receiving Velsipity.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i.** Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
 - ii.** Patient meets at least one of the following (a or b):
 - a)** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR
Note: Examples of assessment for inflammatory response include fecal markers (e.g., fecal calprotectin), serum markers (e.g., C-reactive protein), endoscopic assessment, and/or reduced dose of corticosteroids.
 - b)** Compared with baseline (prior to initiating Velsipity), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or decreased rectal bleeding.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Velsipity is not recommended in the following situations:

- 1. Concurrent Use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drug (DMARD) for Ulcerative Colitis.** In the pivotal trials, patients who received Velsipity were not permitted to receive concomitant treatment with biologics used for the treatment of ulcerative colitis (see [Appendix](#) for examples).¹ Combination therapy is generally not recommended due to a potential for a higher rate of adverse effects with combinations and lack of evidence supporting additive efficacy. There are no data evaluating combination of Velsipity with a targeted synthetic DMARD (e.g., Xeljanz/Xeljanz XR (tofacitinib tablets/extended-release tablets)); therefore, safety and efficacy of this combination is unknown.
- 2.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Velsipity® tablets [prescribing information]. New York, NY: Pfizer; October 2023.
2. Feuerstein JD, Isaac s KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. *Gastroenterology*. 2020;158:1450-1461.
3. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. American College of Gastroenterology clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114:384-413.

APPENDIX

* Not an all-inclusive list of indications (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; TYK2 – Tyrosine kinase 2.